For individuals experiencing intractable pain that persists despite various treatment modalities including medication, nerve blocks, and physical therapy, Stem Cell Therapy is emerging as a promising new option for internal pain relief.
Complex Regional Pain Syndrome (CRPS), fibromyalgia, chronic back pain (particularly pain originating from intervertebral discs), and neuropathic pain represent several refractory conditions that are sources of chronic pain and lead to significant daily life impairment.
For instance, even a light touch can induce excruciating pain, or pain so severe it prevents sleep at night, profoundly impacting not only the patient's life but also that of their family.
In numerous cases where traditional pain relievers or nerve blocks prove insufficient, Stem Cell Therapy, which utilizes the body's own cells to reactivate its inherent healing capabilities, emerges as a novel option to address the root cause of pain.
Why Stem Cells Are Effective for Pain: A Multifaceted Approach to the Mechanisms of Chronic Pain
Chronic pain is more than just intractable pain. Impaired tissue repair, persistent inflammation, and persistent nerve sensitization are interconnected and self-perpetuating issues. Within this intricate context, Mesenchymal Stem Cells (MSCs) have garnered attention as a therapeutic approach capable of facilitating multi-tissue recovery and restoring the body's intrinsic healing capacity.
MSCs can be harvested from bone marrow, adipose tissue, umbilical cord, and other sources, and are widely applied in the field of regenerative medicine. For chronic pain, the following benefits are anticipated.
Regenerating Tissue and Addressing Damage
Underlying persistent pain is a condition where tissues such as joints, intervertebral discs, and nerves remain damaged and unrepaired. Mesenchymal Stem Cells (MSCs) accumulate at these damaged areas and release growth factors that promote cell proliferation and repair (e.g., HGF, TGF-β), thereby supporting tissue regeneration.
For example, when intervertebral discs degenerate and cause pain, reports indicate that MSC administration improves intervertebral disc thickness and flexibility, and reduces nerve compression.
Halting the uncontrolled progression of inflammation and preventing pain amplification.
Another cause of chronic pain is persistent inflammation within the body. When inflammatory cytokines (e.g., TNF-α and IL-1β) are excessively secreted and continuously stimulate nerves and surrounding tissues, pain signals intensify, leading to a vicious cycle.
MSCs secrete anti-inflammatory cytokines (such as IL-10) and suppress inflammatory mediators, thereby breaking this vicious cycle. To draw an analogy, MSCs act as an immune brake against the inflammatory "fire."
Balancing Neural Pathways and Alleviating Pain Signals
When the nerve itself is damaged, the affected nerve becomes hypersensitive, reacting to even minimal stimuli with pain. This is referred to as neuropathic pain, and conventional analgesics are often ineffective.
MSCs secrete NGF (nerve growth factor), BDNF (brain-derived neurotrophic factor), among other factors, and promote the repair of damaged nerves. It is expected to normalize abnormal pain signal transmission by 'rewiring' damaged neural circuits.
Promoting Blood Flow and Preparing a Healing Environment
Inadequate blood flow is often the underlying issue behind poorly healing tissues. Particularly in muscle and tendon tissue, damage in areas with limited vascularization results in prolonged recovery.
MSCs secrete VEGF (vascular endothelial growth factor) and other factors, and exert actions that facilitate microvascular remodeling. Consequently, oxygen and nutrients more readily reach the tissue, enhancing its recovery capacity.
When these effects are considered holistically, it can be stated that MSCs are distinct from symptomatic pain relievers; instead, they represent a treatment aimed at restoring the environment where pain occurs to a normal state. They function akin to a combined 'firefighter' and 'repairman' within the body – this is the essence of Mesenchymal Stem Cells (MSCs).
Key Point
- Chronic pain etiologies include inflammation, tissue damage, and nerve hypersensitivity.
- MSC has various functions to suppress inflammation, repair tissues, and balance nerves.
- Through the enhancement of blood flow, the healing environment can likewise be optimized.
- By addressing the root causes of pain, the treatment approach aims to alleviate symptoms fundamentally.
Addressing the Persistence of Pain – A Disease-Specific Approach to Chronic Pain and Stem Cell Therapy
The characteristics of chronic pain extend beyond its mere intensity. Delayed healing of damaged tissue, persistent inflammation, and excessive nerve sensitivity are complexly intertwined, creating a vicious cycle that cannot be broken by medication or rehabilitation.
In such situations, mesenchymal stem cells (MSCs) have garnered attention as a treatment method capable of addressing the 'root of chronic pain' through the multifaceted actions of tissue regeneration, inflammation suppression, and neuroprotection. Research is currently underway for various diseases. Herein, we introduce the therapeutic potential of MSCs for representative refractory chronic pain conditions.
CRPS: Regulating Inflammation and Nerve Activity in Uncontrolled Pain
CRPS (Complex Regional Pain Syndrome) is a condition that develops following a minor injury or fracture, leading to severe pain, swelling, skin changes, and persistent joint stiffness in the affected area. Its characteristic features include allodynia, where even light touch elicits intense pain, and hypersensitivity to stimuli such as heat, cold, and wind, which can significantly impair daily activities.
This pain is underpinned by a self-perpetuating pain cycle where local inflammation persists and nerves remain hypersensitive. Standard analgesics or nerve blocks do not provide sufficient relief, and patients experience refractory pain.
Mesenchymal Stem Cells (MSCs) have the potential to curb this uncontrolled progression. It is anticipated that the anti-inflammatory cytokines and neurotrophic factors released by MSCs will alleviate inflammation and modulate neural excitability.
Indeed, reports on intravenously administered allogeneic MSC therapy in CRPS patients have demonstrated a reduction in pain scores, improved joint mobility, and enhanced daily living activities. Furthermore, a clinical trial investigating MSC therapy for CRPS is currently underway at the Cleveland Clinic in the U.S., funded by the NIH (U.S. National Institutes of Health), raising hopes for the establishment of future treatment modalities.
Fibromyalgia: Potential for Neural Recalibration in the Hypersensitive Brain
Fibromyalgia is a refractory disease characterized by persistent widespread pain, stiffness, fatigue, and insomnia. It is more prevalent in women, and because its manifestations are not outwardly visible, it is sometimes misconstrued as 'laziness'.
Underlying this is an amplified perception of pain by the brain and central nervous system—a phenomenon known as pain amplification—where stimuli that would typically go unnoticed are recognized as intense pain.
Mesenchymal Stem Cells (MSCs) are garnering attention for their potential to "reset" abnormal neural reactions. A 2023 animal study demonstrated that when MSCs were infused into a mouse model of fibromyalgia, there was a reduction in cerebral inflammatory cytokines, and both neuronal protection and neogenesis were promoted.
It was also reported that the intracellular inflammatory switch (NLRP3 inflammasome) was suppressed, and autophagy, which promotes neuronal self-repair, was activated.
Human clinical trials have just commenced, but regarding the normalization of the nervous system in conditions where pain thresholds have been severely reduced, MSC therapy could represent an entirely novel strategy for fibromyalgia. Looking ahead, the potential for individualized therapies specifically targeting patients with severe symptoms is also expected to advance.
Intervertebral Disc Back Pain: "Regeneration" of Spinal Discs for Pain Relief
Discogenic back pain is a condition characterized by the degeneration of the intervertebral discs, which serve as cushions between the vertebrae, due to age or excessive mechanical stress, leading to nerve compression and chronic back pain.
Traditionally, if medication and rehabilitation do not improve the condition, surgical intervention (intervertebral disc fusion or replacement) is considered. However, neither procedure repairs the intervertebral disc itself. Consequently, these interventions often merely "manage" rather than "cure" the underlying issue.
This approach involves the regeneration of intervertebral discs using stem cells. When MSCs are injected into degenerated intervertebral discs, it is hypothesized that cartilaginous tissue is reformed, thereby reducing neural compression.
In an international collaborative trial, it was reported that a single MSC injection reduced pain by half in over half of the patients, with effects lasting over 12 months. Furthermore, in a separate trial, 67% of patients receiving MSC therapy showed significant improvement in the Oswestry Disability Index (ODI), leading to reduced opioid medication use and the avoidance of surgical intervention.
Clinical research is currently underway in several countries, including Japan. For moderate to severe intervertebral disc degeneration, MSC therapy is anticipated to emerge as a new option, bridging the therapeutic gap between conservative treatment and surgery.
Neuropathic Pain: A First Step to "Reconnecting" Damaged Nerves
Diabetic neuropathy, postherpetic neuralgia, and chronic pain following spinal cord injury, where nerve damage itself is the cause of 'neuropathic pain,' are types of pain that are notoriously difficult to manage. Conventional pain relievers are ineffective, and given the premise that 'nerves cannot regenerate,' treatment options are limited.
However, MSCs release nerve growth factors to injured nerves to promote regeneration, and they also regulate the neural environment by alleviating inflammation around the nerves. Analogously, this is akin to the meticulous repair work involved in reconnecting individual frayed wires.
Reportedly, in a trial involving patients with severe spinal cord injury, the intrathecal administration of MSCs into the subarachnoid space resulted in observed improvements in tactile sensation and bladder function, in addition to pain reduction. Furthermore, in models of diabetic neuropathy, it has been confirmed that MSCs suppress inflammatory cell activity and promote myelin sheath regeneration, contributing to the reduction of neuralgia.
Certainly, individual differences exist in the degree and etiology of damage, meaning it cannot be universally effective. However, as a crucial first step in challenging the notion that 'regeneration is impossible,' the availability of MSC therapy is highly significant.
Key Point
- Ongoing research into MSC therapy is being conducted for chronic pain conditions, including Complex Regional Pain Syndrome (CRPS), fibromyalgia, intervertebral discogenic back pain, and neuropathic pain.
- In every disease, various interventions such as anti-inflammatory measures, neural repair, and tissue regeneration are indicated.
- Research has evolved from animal studies to clinical trials, and a future transition to insurance coverage and standardization of care is anticipated.
- For chronic pain often deemed "incurable," MSC offers hope and promise as a fundamental approach.
Is Stem Cell Therapy Safe? - Side Effects and Future Preparations
Some individuals may perceive regenerative medicine as an unconventional or specialized treatment approach; however, mesenchymal stem cell (MSC) therapies have undergone extensive clinical application worldwide, and a degree of safety has been confirmed.
The risk of rejection and malignancy is very low.
A primary reason for the attention MSCs receive is their low immunogenicity. In principle, if the cells are autologous (from the patient themselves), rejection is not expected. However, even when allogeneic cells (from another individual) are used, MSCs are less susceptible to immune system attack, thereby confirming their high safety profile.
Regarding the risk of malignancy, MSCs are classified as "adult stem cells," and unlike iPS cells, the risk of malignancy due to cellular immaturity is extremely low. In previous clinical studies, no tumor formation directly attributable to MSCs has been reported.
There are individual differences in treatment effects.
The efficacy of MSC therapy is contingent upon the route of administration (transfusion, local injection), the specific cell type utilized, the stage of disease progression, and other contributing factors. Consequently, therapeutic effects do not manifest uniformly across all individuals, necessitating a precise assessment tailored to each patient's unique status.
Furthermore, the dosage, frequency of administration, and the long-term persistence of effects require further elucidation in future clinical research.
Medical Care at a Trusted Facility
Stem Cell Therapy continues to evolve. To achieve its full efficacy and ensure patient safety, it is paramount to undergo treatment in a medical facility responsible for cell quality, the cell culturing environment, and the management of its administration.
We are committed to providing Stem Cell Therapy grounded in scientific evidence and international safety standards, fostering hopeful outcomes by supporting each patient according to their individual status and objectives.
Key Point
- MSCs exhibit low immunogenicity and a very low risk of malignancy, consequently they are assessed as possessing a high safety profile.
- The effects of treatment exhibit inter-individual variability, necessitating the design of optimal care contingent upon the method of administration and the disease stage.
- When selecting medical treatment, it is crucial to choose a medical facility where quality, management, and transparent accountability are clearly defined.
Stem Cells Unveil 'Freedom from Pain' - A New Option
Mesenchymal stem cells (MSCs) are a treatment modality that targets the drivers of chronic inflammation, tissue damage, and abnormal neurological responses within the body, striving for fundamental repair.
Within the field of regenerative medicine, research is ongoing worldwide, and promising applications are emerging for chronic pain conditions that have traditionally been difficult to manage, including CRPS, fibromyalgia, intervertebral disc pain, and neuropathic pain.
Certainly, it requires courage and hope to take the initial step in a situation where the only option until now has been to exercise restraint.
May medical advancements become "a force to face forward and live once again" for many. 23Century will continue to pursue that possibility with integrity.
- A review explaining the multi-faceted actions of MSCs on chronic pain (immune modulation, nerve regeneration, angiogenesis, etc.) and challenges
Advances and Challenges in Cell Therapy for Neuropathic Pain Using Mesenchymal Stem Cells - Case report where stem cell therapy in CRPS patients resulted in pain reduction and functional improvement
Stem Cells for the Treatment of Complex Regional Pain Syndrome (CRPS): A Case Study - A study in which injection of bone marrow-derived MSCs in fibromyalgia model mice showed improvement in pain behavior and suppression of brain inflammation.
Therapeutic efficacy of stem cells in a reserpine-induced fibromyalgia rat model - A prospective comparative trial demonstrating the effectiveness of treatment using autologous MSCs in patients with chronic back pain due to severe lumbar spinal degeneration.
Evaluation of the Efficacy of Autologous Bone Marrow MSCs for Chronic Low Back Pain Secondary to Severe Lumbar Spinal Degeneration: A 12-Month Study - An international collaborative trial where a single MSC injection in patients with degenerative intervertebral disc low back pain reported pain reduction and functional improvement up to 12 months afterward.
A clinical trial demonstrates that stem cell injections alleviate low back pain. - Initial reports where subarachnoid MSC administration in chronic spinal cord injury patients showed a significant pain reduction in about half of the patients.
Intrathecal administration of autologous mesenchymal stem cells improves neuropathic pain in patients with spinal cord injury.